TECTONIC THERAPEUTIC, INC. Payment of Financing and Stock Issuance Costs
TECTONIC THERAPEUTIC, INC. (TECX) reported Payment of Financing and Stock Issuance Costs of $7.41 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaymentOfFinancingAndStockIssuanceCosts · last filed 2024-11-12
- TECTONIC THERAPEUTIC, INC. payment of financing and stock issuance costs for the quarter ending 2024-09-30 was $6.24M.
- TECTONIC THERAPEUTIC, INC. payment of financing and stock issuance costs for the quarter ending 2023-09-30 was $0.00.
- TECTONIC THERAPEUTIC, INC. payment of financing and stock issuance costs for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- TECTONIC THERAPEUTIC, INC. payment of financing and stock issuance costs for fiscal 2019 was $133.00K.
- TECTONIC THERAPEUTIC, INC. payment of financing and stock issuance costs for fiscal 2018 was $0.00.
| Period end | Payment of Financing and Stock Issuance Costs 3 month | Payment of Financing and Stock Issuance Costs 6 month | Payment of Financing and Stock Issuance Costs 9 month | Payment of Financing and Stock Issuance Costs 12 month | Payment of Financing and Stock Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2024-09-30 | $6.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $7.41M 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $1.17M 10-Q · filed 2024-08-14 | ||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-14 | ||||
| 2020-12-31 | $0.00 10-K · filed 2021-03-18 | ||||
| 2019-12-31 | $133.00K 10-K · filed 2021-03-18 | $133.00M 10-K · filed 2020-03-16 | |||
| 2018-12-31 | $0.00 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |